



Results of Special Meeting and ASX Appendix 3X

For Immediate Release:

May 21, 2015

Sydney, Australia – Simavita Limited (“**Simavita**” or the “**Company**”) (TSX-V: SV; ASX: SVA) is pleased to announce the results of the Special Meeting of the Company’s share/CDI holders which was held at 10.00 am today (Australian Eastern time) in North Sydney, Australia.

All four resolutions that were put before the shareholders were passed on a show of hands. Details of the proxy votes received by the Company in respect of these resolutions are contained in the following table:

Description of Resolution	For	Against	Excluded	Totals
1. Approval and ratification of shares				
Numbers of votes received	42,898,231	113,224	-	43,011,455
Percentage of votes cast	99.74%	0.26%	N/A	100.00%
2. Approval of shares to Jackham Investments Pty. Ltd.				
Numbers of votes received	42,818,898	192,557	-	43,011,455
Percentage of votes cast	99.55%	0.45%	N/A	100.00%
3. Approval of shares to Warren Bingham				
Numbers of votes received	42,818,898	192,557	-	43,011,455
Percentage of votes cast	99.55%	0.45%	N/A	100.00%
4. Confirmation of appointment of Warren Bingham to the Board of Directors				
Numbers of votes received	42,849,698	161,757	-	43,011,455
Percentage of votes cast	99.62%	0.38%	N/A	100.00%

Note: The Company currently has a total of **92,159,678** common shares on issue and **996** share/CDI holders.

“We are extremely pleased that Warren has now joined the Simavita Board and we look forward to benefitting from his experience in innovative, first-to-market, disruptive medical technology. His background in strategic planning and commercialisation will benefit Simavita as we continue to drive our global business forward,” commented Simavita CEO, Philippa Lewis.

An ASX Appendix 3X in respect of newly-appointed Director Mr. Bingham is attached.

For further information, please check our website (www.simavita.com) or contact the persons outlined below.

Company	Media and Investor Relations
Philippa Lewis, Chief Executive Officer T: +61 2 8405 6381	<i>In Australia:</i> Jane Lowe, IR Department E: jane.lowe@irdepartment.com.au
Thomas Howitt, Chief Financial Officer T: +61 418 351 127	T: +61 411 117 774

About Simavita

Simavita is a medical device company that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM™ platform technology which is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.

About SIM™

SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit www.simavita.com.

The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Simavita Limited
A.R.B.N.	165 831 309

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Warren Ross Bingham
Date of appointment	21 May 2015

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
None

+ See chapter 19 for defined terms.

Appendix 3X
Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Note: Provide details of the circumstances giving rise to the relevant interest.	
None	

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

Dated: 21 May 2015